{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:09:03Z","timestamp":1761718143428},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,6,4]],"date-time":"2010-06-04T00:00:00Z","timestamp":1275609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s11060-010-0239-0","type":"journal-article","created":{"date-parts":[[2010,6,3]],"date-time":"2010-06-03T19:39:52Z","timestamp":1275593992000},"page":"155-159","source":"Crossref","is-referenced-by-count":15,"title":["Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy"],"prefix":"10.1007","volume":"101","author":[{"given":"Katherine B.","family":"Peters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Vredenburgh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry S.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,4]]},"reference":[{"key":"239_CR1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4103\/0378-6323.16800","volume":"71","author":"G Singh","year":"2005","unstructured":"Singh G, Kumar LP (2005) Striae distensae. Indian J Dermatol Venereol Leprol 71:370\u2013372","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"239_CR2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jaad.2006.12.004","volume":"56","author":"G Yosipovitch","year":"2007","unstructured":"Yosipovitch G, DeVore A, Dawn A (2007) Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol 56:901\u2013916 (quiz 917-920)","journal-title":"J Am Acad Dermatol"},{"key":"239_CR3","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1365-2133.1994.tb04978.x","volume":"131","author":"P Autio","year":"1994","unstructured":"Autio P, Oikarinen A, Melkko J, Risteli J, Risteli L (1994) Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect. Br J Dermatol 131:660\u2013663","journal-title":"Br J Dermatol"},{"key":"239_CR4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1046\/j.1365-2133.2002.04949.x","volume":"147","author":"Y Oishi","year":"2002","unstructured":"Oishi Y, Fu ZW, Ohnuki Y, Kato H, Noguchi T (2002) Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. Br J Dermatol 147:859\u2013868","journal-title":"Br J Dermatol"},{"key":"239_CR5","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1586\/14737175.7.10.1327","volume":"7","author":"FN Daly","year":"2007","unstructured":"Daly FN, Schiff D (2007) Supportive management of patients with brain tumors. Expert Rev Neurother 7:1327\u20131336","journal-title":"Expert Rev Neurother"},{"key":"239_CR6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11940-005-0042-y","volume":"7","author":"AA Pruitt","year":"2005","unstructured":"Pruitt AA (2005) Treatment of medical complications in patients with brain tumors. Curr Treat Options Neurol 7:323\u2013336","journal-title":"Curr Treat Options Neurol"},{"key":"239_CR7","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733\u20134740","journal-title":"J Clin Oncol"},{"key":"239_CR8","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","volume":"13","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE II, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253\u20131259","journal-title":"Clin Cancer Res"},{"key":"239_CR9","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722\u20134729","journal-title":"J Clin Oncol"},{"key":"239_CR10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740\u2013745","journal-title":"J Clin Oncol"},{"key":"239_CR11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","volume":"333","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328\u2013335","journal-title":"Biochem Biophys Res Commun"},{"key":"239_CR12","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1053\/j.seminoncol.2006.08.001","volume":"33","author":"H Hurwitz","year":"2006","unstructured":"Hurwitz H, Saini S (2006) Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 33:S26\u2013S34","journal-title":"Semin Oncol"},{"key":"239_CR13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","volume":"91","author":"FA Scappaticci","year":"2005","unstructured":"Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173\u2013180","journal-title":"J Surg Oncol"},{"key":"239_CR14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1468-3083.2007.02343.x","volume":"22","author":"RC Cordeiro","year":"2008","unstructured":"Cordeiro RC, Moraes AM (2008) Ulceration of striae distensae in a patient with systemic lupus erythematosus. J Eur Acad Dermatol Venereol 22:390\u2013392","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"239_CR15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1087-0024.2000.00014.x","volume":"5","author":"MG Tonnesen","year":"2000","unstructured":"Tonnesen MG, Feng X, Clark RA (2000) Angiogenesis in wound healing. J Investig Dermatol Symp Proc 5:40\u201346","journal-title":"J Investig Dermatol Symp Proc"},{"key":"239_CR16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s00520-001-0333-0","volume":"10","author":"C Hempen","year":"2002","unstructured":"Hempen C, Weiss E, Hess CF (2002) Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 10:322\u2013328","journal-title":"Support Care Cancer"},{"key":"239_CR17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11060-008-9573-x","volume":"88","author":"S Ananthnarayan","year":"2008","unstructured":"Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, Pope WB (2008) Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 88:339\u2013347","journal-title":"J Neurooncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-010-0239-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-010-0239-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-010-0239-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:19:42Z","timestamp":1559362782000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-010-0239-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,4]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["239"],"URL":"https:\/\/doi.org\/10.1007\/s11060-010-0239-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,4]]}}}